Topic
Topic
Eli Lilly's EBGLYSS label update from the FDA allows one subcutaneous maintenance dose every eight weeks for adults with moderate-to-severe atopic dermatitis, extending the previously approved monthl…
Eli Lilly has reported positive phase 3b results for Ebglyss, with the topline disclosure signaling another late-stage win for th…
Eli Lilly's Ebglyss cleared or nearly cleared hand and foot eczema in 53% of patients versus 27% on placebo, per Medical Daily, f…
Lilly reports Phase 3b data showing EBGLYSS (lebrikizumab-lbkz) achieved significant, rapid improvements in skin clearance, itch,…
Lilly's Phase 3b ADtouch trial shows 53% of hand-and-foot atopic dermatitis patients on EBGLYSS reached clear or almost clear ski…
Ebglyss met primary and secondary endpoints at 16 weeks in Phase 3b ADtouch, improving clearance, itch and pain in moderate-to-se…